The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended conditional approval for Takeda Pharmaceuticals and Millennium adcetris (brentuximab vedotin) in Europe. If the CHMP ...
Tags: CHMP, refractory CD30 positive Hodgkin lymphoma, sALCL
Takeda Pharmaceutical Company and Millennium: The Takeda Oncology Company have won European conditional marketing authorization for Adcetris (brentuximab vedotin). Adcetris is indicated for use in adult patients with relapsed or ...
Tags: adcetris, antibody-drug conjugate, Brentuximab vedotin, sALCL